WO2000035945A8 - Agents antifongiques de peptide cyclique possedant un substituant sucre - Google Patents

Agents antifongiques de peptide cyclique possedant un substituant sucre

Info

Publication number
WO2000035945A8
WO2000035945A8 PCT/US1999/029927 US9929927W WO0035945A8 WO 2000035945 A8 WO2000035945 A8 WO 2000035945A8 US 9929927 W US9929927 W US 9929927W WO 0035945 A8 WO0035945 A8 WO 0035945A8
Authority
WO
WIPO (PCT)
Prior art keywords
antifungal agents
cyclic peptide
sugar substituent
peptide antifungal
agent
Prior art date
Application number
PCT/US1999/029927
Other languages
English (en)
Other versions
WO2000035945A1 (fr
Inventor
John Michael Rodriguez
Michael John Nesler
Mark James Zweifel
Original Assignee
Lilly Co Eli
John Michael Rodriguez
Michael John Nesler
Mark James Zweifel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, John Michael Rodriguez, Michael John Nesler, Mark James Zweifel filed Critical Lilly Co Eli
Priority to EP99966327A priority Critical patent/EP1140992A1/fr
Priority to JP2000588202A priority patent/JP2002532513A/ja
Priority to CA002354055A priority patent/CA2354055A1/fr
Priority to AU21895/00A priority patent/AU2189500A/en
Publication of WO2000035945A1 publication Critical patent/WO2000035945A1/fr
Publication of WO2000035945A8 publication Critical patent/WO2000035945A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des composés représentés par la formule (I), R8 représentant une fraction de sucre. Ces composés sont utiles comme agent antifongique et antiparasite ou comme intermédiaire de cet agent. L'invention concerne également des techniques de traitement et des formulations pharmaceutiques contenant les composés représentés par la formule (I).
PCT/US1999/029927 1998-12-16 1999-12-15 Agents antifongiques de peptide cyclique possedant un substituant sucre WO2000035945A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99966327A EP1140992A1 (fr) 1998-12-16 1999-12-15 Agents antifongiques de peptide cyclique possedant un substituant sucre
JP2000588202A JP2002532513A (ja) 1998-12-16 1999-12-15 糖置換基を有する環式ペプチド抗真菌剤
CA002354055A CA2354055A1 (fr) 1998-12-16 1999-12-15 Agents antifongiques de peptide cyclique possedant un substituant sucre
AU21895/00A AU2189500A (en) 1998-12-16 1999-12-15 Cyclic peptide antifungal agents having a sugar substituent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11243398P 1998-12-16 1998-12-16
US60/112,433 1998-12-16

Publications (2)

Publication Number Publication Date
WO2000035945A1 WO2000035945A1 (fr) 2000-06-22
WO2000035945A8 true WO2000035945A8 (fr) 2001-07-05

Family

ID=22343883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029927 WO2000035945A1 (fr) 1998-12-16 1999-12-15 Agents antifongiques de peptide cyclique possedant un substituant sucre

Country Status (5)

Country Link
EP (1) EP1140992A1 (fr)
JP (1) JP2002532513A (fr)
AU (1) AU2189500A (fr)
CA (1) CA2354055A1 (fr)
WO (1) WO2000035945A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011023A2 (fr) 1998-08-20 2000-03-02 Eli Lilly And Company Analogues peptidiques cycliques a systeme cyclique modifie
WO2000034315A2 (fr) 1998-12-09 2000-06-15 Eli Lilly And Company Purification de composes cyclopeptidiques d'echinocandine
AU776782C (en) 1999-03-03 2005-04-07 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
RU2001126723A (ru) 1999-03-03 2003-09-27 Эли Лилли энд Компани (US) Эхинокандин/углеводные комплексы
CA2362482A1 (fr) 1999-03-03 2000-09-08 Eli Lilly And Company Procedes permettant de preparer des compositions et des formulations pharmaceutiques orales d'echinocandine b
ES2270819T3 (es) 1999-03-03 2007-04-16 Eli Lilly And Company Formacion e intercambio anionico de sales de amonio internas cristalinas de equinocandina.
EP3732186A1 (fr) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Inhibiteurs hétérobifonctionnels de e-sélectine et de galectine -3
CA3122321A1 (fr) 2018-12-27 2020-07-02 Glycomimetics, Inc. C-glycosides inhibiteurs de galectine-3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629289A (en) * 1995-07-25 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
WO1997017365A1 (fr) * 1995-11-09 1997-05-15 Merck & Co., Inc. Compose de cyclohexapeptidyle bisamine, compositions contenant ce compose et procedes d'utilisation
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Also Published As

Publication number Publication date
JP2002532513A (ja) 2002-10-02
WO2000035945A1 (fr) 2000-06-22
CA2354055A1 (fr) 2000-06-22
AU2189500A (en) 2000-07-03
EP1140992A1 (fr) 2001-10-10

Similar Documents

Publication Publication Date Title
WO1999063826A3 (fr) Agents pour lutter contre des parasites de vegetaux
IL109615A (en) Cyclic polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
CA2327723A1 (fr) Derives bicycliques de l'acide hydroxamique
AU6801090A (en) Peptide compounds, a process for preparation thereof and pharmaceutical composition comprising the same
CA2166475A1 (fr) Formulations aqueuses, stables, multiphasiques, produit finis pour composes destines a proteger les cultures; methode de preparation
EP0727217A3 (fr) Compositions pharmaceutiques et cosmétiques contenant ellagitannin du type god comme principe actif
HUP9802304A3 (en) Pyridazin-3-one derivatives, intermediates, use thereof, insecticide compositions containing these compounds as active ingredients
CA2199128A1 (fr) Composes a base de dihydrobenzofurane et apparentes utiles en tant qu'agents anti-inflammatoires
WO2004011477A3 (fr) Ketolides pontes aux carbones 6,11-4
WO2000035945A8 (fr) Agents antifongiques de peptide cyclique possedant un substituant sucre
IE860178L (en) 13-beta-alkylmilbemycins
CA2179733A1 (fr) Sulfamates de pseudofructopyranose anticonvulsifs
CA2256718A1 (fr) Dihydrobenzopyranne et composes connexes utiles comme agents anti-inflammatoires
CA2244194A1 (fr) Composes de dihydrobenzofurane utilises comme agents anti-inflammatoires
HUP9801133A3 (en) 1,2,4-triazole-derivatives, fungicide compositions containing these compounds as active ingredients
CA2244196A1 (fr) Dihydrobenzofurane et composes apparentes utilises comme agents anti-inflammatoires
IE870845L (en) N'-substituted-n,n'-diacylhydrazines
CA2244402A1 (fr) Composes de dihydrobenzofurane utilises comme agents anti-inflammatoires
WO1999058527A3 (fr) Derives de benzofuranne, composition pharmaceutique renfermant ces derives et procede de preparation du principe actif
JPS5655397A (en) Aminobenzoic acid ester derivative, and physiologically active agent containing said derivative
CA2304624A1 (fr) Phosphate-esters et hydroxy-esters de tetrahydrofurane utilises comme promedicaments pour agent antifongique correspondant
EP0239527A3 (fr) Composition apte à l'usage comme formulation transdermale
AP2003002881A0 (en) Pesticidal compositions containing silicon compounds
WO1999024042A3 (fr) Composition gelifiante anti-androgenique stable
IE790954L (en) Pharmaceutical formulations containing prostaglandin¹compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2354055

Country of ref document: CA

Ref country code: CA

Ref document number: 2354055

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 588202

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 21895/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999966327

Country of ref document: EP

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 25/2000 DELETE (63)

WWP Wipo information: published in national office

Ref document number: 1999966327

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09868279

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999966327

Country of ref document: EP